 WALTHAM, Mass., May 11, 2021 PRNewswire -- Syndax Pharmaceuticals, Inc. Syndax, the Company or we Nasdaq: SNDX, a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the first quarter ended March 31, 2021. 